Hepion Pharmaceuticals’ $34.5M Follow-on Offering

Blank Rome LLP advised ThinkEquity on the deal while Sheppard Mullin advised Hepion Pharmaceuticals, Inc.

ThinkEquity, a division of Fordham Financial Management, Inc., acted as underwriters’ counsel in connection with a $34.5M follow-on offering of common stock of Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis and liver disease. The transaction was completed on November 30, 2020.

The Blank Rome team was led by Brad Shiffman (Picture), Melissa Murawsky and Maria Carnicella.

The Sheppard Mullin team included partner Jeff Fessler and associate Justin Anslow. Partner Jing Liu assisted on IP matters.

Involved fees earner: Maria Carnicella – Blank Rome LLP; Brad Shiffman – Blank Rome LLP; Justin Anslow – Sheppard Mullin; Jeffrey Fessler – Sheppard Mullin; Jing Liu – Sheppard Mullin;

Law Firms: Blank Rome LLP; Sheppard Mullin;

Clients: Hepion Pharmaceuticals; ThinkEquity;

Print Friendly, PDF & Email

Author: Ambrogio Visconti